About Acute Radiation Syndrome
About Acute Radiation Syndrome (ARS)
Several radiation dose- and time-dependent sub-syndromes and complications occur after acute high-dose radiation exposure. These complications define ARS. Two key sub-syndromes responsible for early mortality are the hematopoietic (H-ARS) and gastrointestinal (GI-ARS) syndromes, followed by delayed effects to the lung known as delayed effect of acute radiation exposure (“DEARE”). DEARE-lung injury is characterized by pneumonitis (PN) and fibrosis, which may lead to respiratory failure.
Currently there are no U.S. Food and Drug Administration (FDA)-approved drugs for the treatment of either ARS or DEARE related pulmonary injury. For this reason, Aeolus is developing its lead clinical stage candidate compound, AEOL 10150, for the treatment of both pulmonary ARS and DEARE.